GRAL

GRAIL, LLC
NASDAQHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$2.76B
P/E Ratio
EPS
$-10.30
Beta
3.22
52W High
$118.84
52W Low
$29.95
50-Day MA
$66.31
200-Day MA
$74.31
Dividend Yield
Profit Margin
-253.20%
Forward P/E
PEG Ratio

About GRAIL, LLC

GRAIL, LLC is a leading biotechnology firm specializing in advanced cancer diagnostics, particularly through its innovative blood tests designed for multi-cancer early detection (MCED). Utilizing proprietary genomic technologies, the company is committed to enhancing precision medicine by offering vital insights for proactive health management and improving patient outcomes. GRAIL is poised to address critical gaps in cancer screening and diagnostics, establishing itself as a pivotal entity in the dynamic oncology landscape, with the potential to significantly impact the future of cancer care.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$156.12M
Gross Profit (TTM)$76.94M
EBITDA$-360.50M
Operating Margin-332.90%
Return on Equity-16.10%
Return on Assets-11.40%
Revenue/Share (TTM)$4.07
Book Value$60.79
Price-to-Book1.15
Price-to-Sales (TTM)17.71
EV/Revenue13.41
EV/EBITDA
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)28.10%
Shares Outstanding$42.92M
Float$33.44M
% Insiders5.23%
% Institutions83.53%

Historical Volatility

HV 10-Day
50.68%
HV 20-Day
51.74%
HV 30-Day
53.10%
HV 60-Day
67.46%
HV Rank

Volatility is currently contracting

Analyst Ratings

Consensus ($70.12 target)
4
Buy
5
Hold

Latest News

GRAL INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of the August 4, 2026 Lead Plaintiff Deadline in the Grail, Inc. Securities Class Action

ATLANTA, July 29, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Grail, Inc. (“Grail”) (NASDAQ: GRAL). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts regarding the probability of achieving the primary endpoint of a statistically significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial.

GlobeNewsWire7/29/2026Neutral
TUESDAY DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Grail Class Action Lawsuit - GRAL

SAN DIEGO, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, both dates inclusive (the “Class Period”), have until Tuesday, August 4, 2026 to seek appointment as lead plaintiff of the Grail class action lawsuit. Captioned Robbins v.

GlobeNewsWire7/29/2026Neutral
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

SAN FRANCISCO, July 29, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in GRAIL, Inc. (NASDAQ: GRAL) that a securities fraud class action lawsuit has been filed, and the firm is actively urging investors with substantial losses to submit your losses now . The upcoming lead plaintiff deadline is August 4, 2026.

PRNewsWire7/29/2026Neutral
Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

The Red Flags: What Grail Insiders Allegedly Knew About NHS-Galleri's Insufficient Timeline Before Shareholders Learned the Trial Failed Its Primary Endpoint, Costing Investors $51.32 Per Share NEW YORK, July 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Grail, Inc. (NASDAQ: GRAL). YOU MAY BE AFFECTED IF YOU: Purchased Grail stock between May 13, 2025, and February 19, 2026 Lost money on your GRAL investment Submit your information to recover losses or contact Joseph E.

PRNewsWire7/29/2026Neutral
GRAIL, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 4, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds GRAIL, Inc. (“GRAIL” or the “Company”) (NASDAQ: GRAL) investors of the August 4, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join The GRAIL Class Action Lawsuit : Do you, or did you, own shares of GRAIL, Inc. (NASDAQ: GRAL)?

GlobeNewsWire7/29/2026Neutral
GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in GRAIL, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/grail-class-action-lawsuit.

GlobeNewsWire7/29/2026Neutral
GRAL IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action - GRAL

New York, New York--(Newsfile Corp. - July 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the "Class Period"), of the important August 4, 2026 lead plaintiff deadline. SO WHAT: If you purchased GRAIL common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp7/29/2026Neutral
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GRAIL, Inc. of Class Action Lawsuit and Upcoming Deadlines – GRAL

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against GRAIL, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL).   Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

GlobeNewsWire7/28/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GRAL and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026